In some of the first Belviq cases that have been filed, the complaints allege that Arena Pharmaceuticals, Inc. designed and developed both Belviq and Belviq XR. Arena Pharmaceuticals, Inc. is a Delaware corporation with its principal place of business located at 6154 Nancy Ridge Drive, San Diego, California 92121. Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company's most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn's disease. In 2016, the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials. In December 2021, Pfizer announced that it had agreed to acquire Arena for $6.7 billion in cash. In March 2022, it was announced the acquisition by Pfizer had been concluded.
Have You Been Diagnosed with Cancer After Using Belviq?
YOU MAY BE ENTITLED TO COMPENSATION. COMPLETE THE FORM BELOW FOR A FREE CASE EVALUATION.
Arena received FDA approval for Belviq, also known as lorcaserin hydrochloride, on June 27, 2012, as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adult patients with a body mass index (hereinafter referred to as “BMI”) greater than or equal to 30 kg/m2 or adult patients with a BMI greater than or equal to 27 kg/m2 and at least one weight- related comorbid condition.
Arena received additional FDA approval for Belviq XR, an extended release tablet of lorcaserin hydrochloride, on July 15, 2016 for the same indication as Belviq (hereinafter Belviq and Belviq XR will be collectively referred to as “Belviq”).
The cases also name Eisai, Inc. as a named defendant and allege that Eisai marketed, sold and distributed Belviq and Belviq XR throughout the United States. Eisai, Inc. is also a a Delaware corporation with its principal place of business at 100 Tice Boulevard, Woodcliff Lake, New Jersey 07677. Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.
Up until approximately 2017, Defendants had a joint contractual agreement in which Arena manufactured Belviq and Eisai marketed, distributed, and sold Belviq. In or around January 2017, Eisai purchased the global rights to develop and market Belviq from Arena.